Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-VIP monoclonal antibodies
- Development stage
- Preclinical
- Lead developer
- Emory University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Anti-VIP monoclonal antibodies are humanized therapeutic agents designed to neutralize Vasoactive Intestinal Polypeptide (VIP), a 28-amino acid neuropeptide and hormone that exhibits potent immunosuppressive properties. In the microenvironment of hematological malignancies such as Acute Myeloid Leukemia (AML), VIP is frequently upregulated and serves as a co-inhibitory ligand that downregulates T cell anti-leukemia activity by signaling through its receptors, VPAC1 and VPAC2. By sequestering VIP, these monoclonal antibodies (including clones A6, C2, and D5) block this inhibitory pathway, thereby restoring and enhancing T cell-mediated anti-tumor responses. Developed by researchers at Emory University's Winship Cancer Institute, these antibodies have demonstrated superior in vitro T cell activation and improved survival in preclinical mouse models of myeloid sarcoma compared to peptide-based VIP receptor antagonists like ANT-308.
- Other names
- humanized anti-VIP monoclonal antibodiesanti-vasoactive intestinal polypeptide monoclonal antibodies
Beyond the preview
Go deeper on anti-VIP monoclonal antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-VIP monoclonal antibodies.